Business Context and Reporting Period
This Form 6-K filing by Gauzy Ltd. covers the month of December 2025, with the report dated December 3, 2025. The company, headquartered in Tel Aviv, Israel, operates in the light and vision control products sector, targeting OEMs and Tier 1 suppliers in aeronautics and automobile markets. The filing primarily addresses recent funding transactions and significant changes to the Board of Directors.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period. However, it details the following capital and liquidity events:
- Capital Raised: The Company raised a total of $12 million in new cash.
- Primary Investment: $11 million received via Share Issuance Agreements with existing investors (including Chutzpah Holdings). This is structured as an advance pending the issuance of ordinary shares or pre-funded warrants at 70% of the reference price, or a convertible loan.
- Senior Lender Advance: $1 million received from Orion Infrastructure Capital (OIC) via a limited waiver to the existing Note Purchase Agreement.
- Debt Treatment: OIC waived cash payment of accrued interest for Q3 2025, which will be paid in kind by December 31, 2025, or treated as additional borrowings under a potential Convertible Loan.
Material Changes
Significant corporate governance changes occurred on December 2, 2025:
- Director Resignations: Jesse Ezriel Klein and Alejandro Weinstein resigned from the Board of Directors and all committees effective immediately to pursue other interests.
- Listing Compliance: Following the resignations, the Board consists of only three members, with only two being independent (Eyal Peso is not independent). This renders the Audit Committee non-compliant with Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent directors.
- Cure Period: The Company has a cure period to regain compliance extending until the earlier of its next annual meeting or one year from the resignation date. Failure to comply could result in delisting proceedings.
Outlook, Risks, and Contingencies
Management continues to seek additional funding to support global operations. The filing highlights several material risks and contingencies:
- Insolvency Proceedings: Ongoing insolvency proceedings in France may impact operations and financial condition.
- Product Validation: No assurance exists that the Company will win production models with OEMs in the aeronautics and automobile sectors.
- Financial Condition: The Company is an early growth-stage entity with a history of losses and expects to continue incurring significant losses.
- Capital Needs: Additional capital may be required before profitability is achieved; failure to secure this capital could force delays or termination of product development.
- External Factors: Risks include global economic disruptions (e.g., Russia-Ukraine conflict), supply chain issues, and regulatory compliance across multiple jurisdictions.
Investor Verification Checklist
- Verify the final settlement terms of the $11 million Share Issuance Agreements (equity issuance vs. convertible loan) and the specific "Reference Price" calculation.
- Confirm the timeline for appointing a new independent director to restore Nasdaq Audit Committee compliance.
- Monitor the status of insolvency proceedings in France and their specific impact on assets or operations.
- Review the full text of the Share Issuance Agreements and Note Purchase Agreement waivers when filed as exhibits to the Form 20-F.
- Assess the Company's runway given the expectation of continued significant losses and the need for further capital raises.